Natco Pharma appoints TC Mallikarjun as Vice President - QC at Kothur Pharma Division

Published On 2025-08-01 06:00 GMT   |   Update On 2025-08-01 06:00 GMT
Advertisement

Hyderabad: Natco Pharma has announced the appointment of T.C. Mallikarjun as Vice President - QC at Pharma Division, Kothur of the Company.

T.C. Mallikarjuna has experience in the leading Indian Pharma Manufacturing Industries. He also has experience in handling regulatory Inspections like USFDA, MHRA, TGA, ANVISA, etc., and managing new products and exhibit validations. He was associated with Aurobindo Pharma Limited, Hyderabad, as Senior General Manager - Head QC before joining the Company.
The appointment comes amid a series of key leadership changes at Natco Pharma in recent months. In July, Dr Muddasaani Pulla Reddy, Executive Vice President - R & D and CH Srinivas, Senior Vice President - Demand & Supply superannuated from Natco Pharma. In addition, R. Sridhar Reddy – Senior Vice President – GCQA also resigned from the Company.
Earlier in June, Natco Pharma appointed Yarramshetty Krishna Rao as Senior Vice President - Operations at Mekaguda of the Company. 
Advertisement

In May, the company named Dilip Manikchand Dhore as Vice President – Corporate Quality Assurance, and Amber Roy as Associate Vice President – Distribution. Additionally, Addagada Veeranarayana and Parupalli Sreenivasa Rao were appointed Associate Vice Presidents – Operations, while Kurada Venkata Maruti Ramchander was designated as Associate Vice President – Regulatory Affairs.

Read also: Natco Pharma offers to acquire stake in South African pharma firm Adcock Ingram Holdings for Rs 2000 crore

NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven company in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.

Read also: Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President - Operations at Mekaguda

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News